Pacific Biosciences of California (NASDAQ:PACB) Stock Price Target Raised at Barclays

Pacific Biosciences of California (NASDAQ:PACB) had its price objective hoisted by Barclays from $1.25 to $2.00 in a report released on Thursday morning,Benzinga reports. Barclays currently has an underweight rating on the biotechnology company’s stock.

Several other equities research analysts also recently commented on PACB. Wall Street Zen downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Piper Sandler reiterated a “neutral” rating and set a $3.00 price objective (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday. UBS Group assumed coverage on Pacific Biosciences of California in a report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 target price for the company. Finally, Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $2.09.

Pacific Biosciences of California Stock Down 4.7%

Shares of PACB stock opened at $2.43 on Thursday. The stock has a 50-day simple moving average of $1.91 and a 200 day simple moving average of $1.62. Pacific Biosciences of California has a fifty-two week low of $1.07 and a fifty-two week high of $3.43. The stock has a market capitalization of $755.32 million, a P/E ratio of -5.79 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. The company had revenue of $40.56 million during the quarter, compared to analyst estimates of $39.31 million. On average, sell-side analysts anticipate that Pacific Biosciences of California will post -0.52 earnings per share for the current year.

Insider Activity at Pacific Biosciences of California

In related news, insider James Gibson, II sold 661,815 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the transaction, the insider owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. This represents a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of Pacific Biosciences of California stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the sale, the insider owned 2,705,853 shares of the company’s stock, valued at $3,057,613.89. This trade represents a 0.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PACB. BlackRock Inc. bought a new position in Pacific Biosciences of California in the 2nd quarter worth $54,330,000. Bank of America Corp DE bought a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $2,265,000. Hhlr Advisors LTD. bought a new stake in Pacific Biosciences of California during the 2nd quarter valued at approximately $1,544,000. Carret Asset Management LLC grew its holdings in Pacific Biosciences of California by 1.2% in the 3rd quarter. Carret Asset Management LLC now owns 607,140 shares of the biotechnology company’s stock valued at $1,439,000 after buying an additional 7,000 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Pacific Biosciences of California during the second quarter worth approximately $1,290,000.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported a Q3 loss of $0.11 per share, narrower than analysts’ expected $0.13 loss. Revenue of $40.56 million also topped the $39.31 million consensus estimate. PacBio Q3 2026 results
• Positive Sentiment: Piper Sandler raised its price target to $3 from $2 while maintaining a Neutral rating, signaling greater potential upside in its view. Piper Sandler rating
• Neutral Sentiment: The company narrowed its 2026 revenue outlook to $155 million–$160 million and continues to target cash-flow breakeven in 2028. The tighter range may offer more clarity, while the breakeven timeline highlights that profitability remains years away. Revenue guidance and breakeven target
• Neutral Sentiment: PacBio announced CFO changes; the available report headline does not provide details on the transition or its expected impact. CFO changes announcement
• Negative Sentiment: Barclays raised its target to $2 from $1.25 but retained an Underweight rating, indicating it still sees downside from the referenced share price. That cautious stance contrasts with Piper Sandler’s higher target. Barclays rating

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.